OncoMatch/Clinical Trials/NCT07186621
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Is NCT07186621 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Sintilimab for hepatocellular carcinoma (hcc).
Treatment: Sintilimab — This study is an open-label, randomized controlled, multicenter, phase III clinical trial
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: targeted therapy (tyrosine kinase inhibitors)
Previous anti-HCC therapies, including but not limited to: targeted therapy (e.g., tyrosine kinase inhibitors)
Cannot have received: immune checkpoint inhibitor (PD-1/PD-L1 inhibitors)
Previous anti-HCC therapies, including but not limited to: immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors)
Cannot have received: systemic chemotherapy
Previous anti-HCC therapies, including but not limited to: systemic chemotherapy
Cannot have received: radiotherapy
Previous radiotherapy involving the abdomen
Lab requirements
Blood counts
Hb≥80g/L，ANC≥1.0×10^9 /L，PLT≥40×10^9 /L
Kidney function
Serum creatinine (CRE) and BUN ≤2.5× ULN
Liver function
Child-Pugh Class: A5, A6, or B7; ALT ≤2.5× ULN (if HBV/HCV positive, ALT ≤1.5× ULN). If ALT ≤1.5× ULN, AST ≤6× ULN (excluding AST elevation due to myocardial infarction). If ALT 1.5-2.5× ULN, AST ≤2.5× ULN.
Cardiac function
No significant ECG abnormalities and no severe cardiac dysfunction
Child-Pugh Class: A5, A6, or B7. ALT ≤2.5× ULN (if HBV/HCV positive, ALT ≤1.5× ULN). If ALT ≤1.5× ULN, AST ≤6× ULN (excluding AST elevation due to myocardial infarction). If ALT 1.5-2.5× ULN, AST ≤2.5× ULN. Serum creatinine (CRE) and BUN ≤2.5× ULN. Hb≥80g/L，ANC≥1.0×10^9 /L，PLT≥40×10^9 /L. No significant ECG abnormalities and no severe cardiac dysfunction.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07186621 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages